| 1 |
Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus [J]. Ann Rheum Dis, 2019, 78 (6): 736-745.
|
| 2 |
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes [J]. Arthritis Rheum, 1999, 42 (4): 599-608.
|
| 3 |
Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs[J]. Ann Rheum Dis, 2010, 69 (12): 2074-2082.
|
| 4 |
Li X, Xiang X, Sun J, et al. Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: a real world single center study[J]. Mod Rheumatol, 2020, 30 (2): 321-326.
|
| 5 |
Magro-Checa C, Steup-Beekman GM, Huizinga TW, et al. Laboratory and neuroimaging biomarkers in neuropsychiatric systemic lupus erythematosus: where do we stand, where to go?[J]. Front Med (Lausanne), 2018 (5): 340.
|
| 6 |
Abe G, Kikuchi H, Arinuma Y, et al. Brain MRI in patients with acute confusional state of diffuse psychiatric / neuropsychological syndromes in systemic lupus erythematosus [J]. Mod Rheumatol, 2017, 27 (2): 278-283.
|
| 7 |
沈思钰，孔伟东，蔡辉. 神经精神狼疮的神经影像学诊断新进展[J]. 中华风湿病学杂志，2007,11(4):250-253.
|
| 8 |
Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of Ⅳ cyclophosphamide versus Ⅳ methylprednisolone in severe neurological manifestations in systemic lupus erythematosus[J]. Ann Rheum Dis, 2005, 64 (4): 620-625.
|
| 9 |
Fanouriakis A, Pamfil C, Sidiropoulos P, et al. Cyclo-phosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study[J]. Lupus, 2016, 25 (6): 627-636.
|
| 10 |
周丽，忻霞菲，覃文，等. 小剂量利妥昔单克隆抗体治疗重症狼疮的疗效和安全性分析[J/CD]. 中华危重症医学杂志（电子版），2018,11(2):110-114.
|
| 11 |
Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature [J]. J Affect Disord, 1983, 5 (4): 319-332.
|
| 12 |
王宝. B淋巴细胞刺激因子相关生物制剂治疗系统性红斑狼疮研究进展[J]. 临床合理用药，2011,4(9C):135-136.
|
| 13 |
Wen J, Stock AD, Chalmers SA, et al. The role of B cells and autoantibodies in neuropsychiatric lupus [J]. Autoimmun Rev, 2016, 15 (9): 890-895.
|
| 14 |
George-Chandy A, Trysberg E, Eriksson K. Raised in-trathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms[J]. Arthritis Res Ther, 2008, 10 (4): R97.
|
| 15 |
谢文慧，张卓莉. 贝利尤单抗治疗系统性红斑狼疮：现状与展望[J]. 中华风湿病学杂志，2020,24(7):495-499.
|
| 16 |
Plüв M, Tampe B, Niebusch N, et al. Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus[J]. Front Med (Lausanne), 2020 (7): 222.
|
| 17 |
Collins CE, Dall'Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA[J]. Lupus Sci Med, 2016, 3 (1): e000118.
|
| 18 |
Sthoeger Z, Lorber M, Tal Y, et al. Anti-BLyS treatment of 36 Israeli systemic lupus erythematosus patients[J]. Isr Med Assoc J, 2017, 19 (1): 44-48.
|